TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03706963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: -phone call 7 days (+/- 2 days) into preoperative period
Study: NCT04097886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Exercise
Description: moderate intensity exercise (70% VO2 max) each morning for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening Exercise
Description: moderate intensity exercise (70% VO2 max) each evening for 5 days
Study: NCT02292043

Intervention type: DRUG
Intervention: HTEA
Description: HTEA

Intervention type: DRUG
Intervention: HTEA
Description: HTEA
Study: NCT04936217

Intervention type: OTHER
Intervention: Data collection
Description: For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
Study: NCT00637091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab, irinotecan
Description: cetuximab, irinotecan
Study: NCT00985231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision Multi-Focal contact lenses
Description: Contact lenses to be worn on a daily wear basis for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofLens59 contact lens
Description: Contact lenses to be worn on a daily wear basis for 2 weeks.
Study: NCT04936217

Intervention type: OTHER
Intervention: Interview using a validated questionnaire
Description: A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
Study: NCT00058058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
Study: NCT02988596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Active Rehabilitation
Description: Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Graded Exertion
Description: Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
Study: NCT01335789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 40 IUs
Study: NCT05695573

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
Description: Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
Description: Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
Description: Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
Description: Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
Study: NCT01283646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apevitin BC
Description: 3.5 to 5 ml 3 times a daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B Complex + Vitamin C
Description: 3.5 to 5 ml 3 times a daily
Study: NCT03980210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: 1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA
Study: NCT00849147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Bone Marrow Transplantation
Description: The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days
Study: NCT00533039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib (A-002)
Description: 250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
Study: NCT01668342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS assessments & feedback
Description: Daily symptom assessments tied to tailored feedback
Study: NCT04672473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CTL
Description: DAC combined with Ag-CTL
Study: NCT02157402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing activities and pop-up events to promote healthy lifestyles
Study: NCT01364519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Dry powder for inhalation, Single Dose, 500mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Fluticasone Propionate
Description: Dry powder for inhalation, Single Dose, placebo
Study: NCT01530009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
Study: NCT02212717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gallbladder drainage (EGBD)
Description: The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous cholecystostomy (PC)
Description: Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
Study: NCT03952988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic ice cream
Description: One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
Study: NCT02680756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Maltol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxy Maltose
Study: NCT03952988

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ice cream
Description: One portion (50g) of an ice-cream without probiotic every day for 4 weeks
Study: NCT00277160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (pegfilgrastim)
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (pegfilgrastim)
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
Study: NCT02389699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Boost with 20 Gy during BCS, EBRT with 46-50 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast radiation
Description: whole breast radiation after BCS with 46-50 Gy
Study: NCT01235442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1=Etanercept
Description: 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2=Clobetasol propionate foam
Description: 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
Study: NCT04805619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomime Morph, a tapered drug eluting stent (DES) with hybrid design
Description: Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
Study: NCT02430207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary pacing femoral vein
Description: Temporary pacing via femoral or subclavian vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary pacing subclavian vein
Study: NCT03290521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No washing
Description: no washing
Study: NCT04586751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs block
Description: Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no Pecs block
Description: no regional block will be performed in this arm
Study: NCT03988062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrelliX Embolic Coil System
Description: Embolic coil with shape memory polymer
Study: NCT04659343

Intervention type: OTHER
Intervention: Measurement of concentration of active metabolite in cancer treatment.
Description: Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
Study: NCT00853684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXCE
Description: Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
Study: NCT02805387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Bicarbonate was ingested
Study: NCT03377855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default Prescribing Change
Description: In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
Study: NCT03298464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM313
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: White to off-white round tablet
Study: NCT01176799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
Study: NCT02013037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.
Study: NCT01912001

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up

Intervention type: OTHER
Group type: OTHER
Intervention: Sympton Assessment
Study: NCT02094261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
Study: NCT03761654

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Longitudinal Strain measure
Description: Global Longitudinal Strain measure on day 1 of hospitalization
Study: NCT02783157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)
Description: Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LLVNS
Description: A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
Study: NCT00465985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00285558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with peer-enhanced activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT with supervised aerobic exercise
Study: NCT04284553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster Alert
Description: Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster Alert
Description: Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold State outreach
Description: An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold State outreach
Description: An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
Study: NCT02165891

Intervention type: DRUG
Group type: OTHER
Intervention: insertion of a chest drain with urokinase instillation
Description: Other interventions except drainage procedure are the same in both arms

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary video-assisted thorascopic surgery
Study: NCT00608348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic glucose clamp procedures
Description: 2 hours of either euglycemic or hypoglycemic glucose clamping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: 90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
Study: NCT04417712

Intervention type: DEVICE
Intervention: KONAR-MF™ VSD Occluder
Description: All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
Study: NCT02702921

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon's 'standard of care' stapler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethicon Powered Vascular Stapler
Study: NCT03317353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: CDP
Description: Vestibular rehabilitation, ten sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: optokinetic stimuli
Description: Vestibular rehabilitation, ten sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: home exercises
Description: Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
Study: NCT03302156

Intervention type: DRUG
Group type: OTHER
Intervention: PSMA-based 18F-DCFPyL PET tracer
Description: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer

Intervention type: DRUG
Group type: OTHER
Intervention: PSMA-based 18F-DCFPyL PET tracer
Description: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer

Intervention type: DRUG
Group type: OTHER
Intervention: PSMA-based 18F-DCFPyL PET tracer
Description: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
Study: NCT01701154

Intervention type: OTHER
Intervention: respiratory muscle strength training